- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05903924
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
March 18, 2025 updated by: Vanda Pharmaceuticals
Motion Serifos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
316
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 94607
- Pacific Research Partners
-
San Jose, California, United States, 95124
- Lumos Clinical Research
-
Santa Monica, California, United States, 90404
- Santa Monica Clinical Trials
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02169
- Beacon Clinical Research
-
-
New York
-
New York, New York, United States, 10016
- Manhattan Medical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- History of motion sickness
- Age 18-75
Exclusion Criteria:
- Nausea-inducing disorder other than motion sickness
- BMI>40
- History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Oral Capsule
|
|
Experimental: Tradipitant High Dose
|
Oral Capsule
|
|
Experimental: Tradipitant Low Dose
|
Oral Capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevention of Vomiting Measured by Vomiting Assessment (VA)
Time Frame: 1 day
|
Prevention of vomiting measured by Vomiting Assessment (VA) score.
The VA is a 1-item questionnaire to objectively measure the incidence of emesis.
Participants will indicate whether or not they have vomited.
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 9, 2023
Primary Completion (Actual)
April 6, 2024
Study Completion (Actual)
April 24, 2024
Study Registration Dates
First Submitted
June 5, 2023
First Submitted That Met QC Criteria
June 5, 2023
First Posted (Actual)
June 15, 2023
Study Record Updates
Last Update Posted (Actual)
April 4, 2025
Last Update Submitted That Met QC Criteria
March 18, 2025
Last Verified
March 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VP-VLY-686-3404
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Motion Sickness
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness, Space | Motion Simulation | Parabolic FlightUnited States
-
Istanbul Aydın UniversityCompletedVestibular Rehabilitation in MS | Motion Sickness, Space | Visually Induced Motion SicknessTurkey (Türkiye)
-
Repurposed Therapeutics, Inc.National Aeronautics and Space Administration (NASA)RecruitingMotion Sickness | Sea Sickness | Motion Sickness, SpaceUnited States
-
Faisal_Karmali@MEEI.HARVARD.EDUMassachusetts Institute of Technology; National Space Biomedical Research InstituteCompleted
-
Naval Aeromedical Research Unit, DaytonUnknownPrevention of Nausea Associated With Motion Sickness | Treatment of Nausea Associated With Motion SicknessUnited States
-
Wingate Institute of NeurogastroenterologyCompletedVisually Induced Motion Sickness in Healthy VolunteersUnited Kingdom
-
University Hospital, CaenCompleted
-
United States Army Aeromedical Research LaboratoryAlabama College of Osteopathic Medicine; Department of Aviation Medicine, U...CompletedMotion SicknessUnited States
-
Repurposed Therapeutics, Inc.TerminatedMotion SicknessUnited States
-
Vanda PharmaceuticalsCompletedMotion SicknessUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States